Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Reports 16-Percent Decline in Q1 Revenues, Narrowed Loss

NEW YORK, May 9 (GenomeWeb News) - Sequenom today reported a 16-percent drop in revenues amidst narrowed losses for the first quarter of 2005.


Revenues for the quarter ended March 31 fell to $4.3 million from $5.1 million during the first quarter of 2004. Revenues were "impacted" this quarter by conditions Sequenom granted to new customers that enable it to recognize some revenues later this year.


"We believe that our MassArray products continue to gain traction in the clinical research market," with 130 systems installed so far, said acting-CEO and CFO Steve Zaniboni in a statement.


Research and development expenses fell to $3.2 million from $5.5 million during the same quarter last year.


Sequenom's net loss for the quarter narrowed to $7.4 million, or $.18 per share, from $9.9 million, or $.25 per share, during the year-ago period.


As of March 31, Sequenom had $31.4 million in cash, cash equivalents, short-term investments, and restricted cash.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.